The Cause
The Chicago Lung Run is held each year in support of lung cancer survivors and their families, and in memory of those who have lost their lives to lung cancer, the leading cancer killer in America. The mission of the Chicago Lung Run is to raise awareness of lung cancer and to raise much-needed funds for lung cancer research.
The 2011 Astellas Chicago Lung Run will benefit cutting-edge lung cancer research through:
Your Donations at Work
Proceeds from the Chicago Lung Run are funding important research projects around the country. For example, the 2009 race helped fund the following research:
Serum proteomics on patients treated with erlotinib
Mary Jo Fidler, MD; Rush University Medical Center
Non-small cell lung cancer (NSCLC) is one of 2 types of lung cancer. It accounts for 85 – 90% of all lung cancers. People diagnosed with NSCLC may respond differently to different types of treatment for NSCLC. Dr. Fidler seeks to identify biomarkers, or molecules, in cells and fluids that can help predict an individual’s response to a certain treatment for NSCLC. Ultimately, this research will help the medical community treat NSCLC more effectively.
Proteomic Analysis of Serum and Tumor Tissue in Small Cell Lung Cancer
Marta Batus, MD; Rush University Medical Center
Small cell lung cancer (SCLC) is one of 2 types of lung cancer, and about 10-15% of all lung cancers are SCLC. Dr. Batus is studying molecules found in blood and tissue (called biomarkers) that are associated with SCLC. Specifically, Dr. Batus’ research aims to identify: 1) biomarkers that are characteristic of small cell lung cancer; 2) biomarkers that will predict response to chemotherapy and resistance to treatment for SCLC; 3) biomarkers that will predict survival in SCLC; and 4) biomarkers that predict the likelihood of the SCLC spreading to the brain. This research will ultimately help the medical community detect and treat SCLC more effectively.